Basilea's Eczema Drug Alitretinoin Meets US Late-stage Study Goals NASDAQ PK) on Monday said a US phase 3 study with its investigational compound oral alitretinoin in patients with severe chronic hand eczema refractory to potent topical corticosteroids met study endpoints. The Swiss biopharmaceutical firm said 40 percent of ... |
